PT-141 for Women: Female Libido and Sexual Wellness Research

Most sexual health content in the peptide space is written as if the physiology were the same across sexes and the only difference were dosing. It is not. Low sexual desire in women has a different mechanistic profile, a different evidence base, and — in PT-141's case — the only approved indication is specifically in women.

Why PT-141 Is Mechanistically Different

Most erectile dysfunction treatments are vascular. PDE5 inhibitors — sildenafil, tadalafil — increase blood flow to genital tissue. They address the physical response.

PT-141, or bremelanotide, works centrally. It is a melanocortin receptor agonist, acting primarily at MC4R in the central nervous system. It affects the neural pathways underlying sexual desire rather than the vascular response.

This distinction is the whole point for female sexual dysfunction, where the limiting factor is frequently desire rather than physical arousal capacity — which is precisely why vascular agents have performed poorly in women in trials.

The Approval and the Evidence

Bremelanotide was approved by the FDA in 2019 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women.

That approval is narrow and worth reading precisely:

• Premenopausal women only. It was not approved for postmenopausal women, where efficacy was not established.
• HSDD specifically — persistent, distressing lack of sexual desire not attributable to another medical or psychiatric condition, medication, or relationship problem. The distress criterion matters: low desire without distress is not a disorder.
• It is administered subcutaneously on demand, roughly 45 minutes before anticipated activity, not on a daily schedule.

What the Trials Showed

The RECONNECT trials demonstrated statistically significant improvements in desire and in distress associated with low desire, compared with placebo.

Effect sizes were modest. This is a genuine effect that helps some women meaningfully, not a transformative one, and the placebo response in sexual function trials is consistently large.

Side Effects Worth Knowing

• Nausea is the most common and is not a minor footnote — it occurred in roughly 40% of trial participants and led a meaningful number to discontinue.
• Flushing and headache are common.
• Transient blood pressure increase with a small heart rate decrease; the label advises against use in uncontrolled hypertension or known cardiovascular disease.

• Hyperpigmentation — focal darkening of skin or gums, more likely with frequent use, which is why dosing frequency is limited.
• Use is limited to no more than one dose in 24 hours and no more than eight per month.

The Broader Picture for Female Desire

PT-141 addresses one mechanism. Low desire in women commonly has several contributors at once, and a competent evaluation looks at all of them:

• Hormonal — the low-estrogen state of postmenopause or lactation causing genitourinary symptoms and dyspareunia; low testosterone affecting desire directly
• Medication — SSRIs are a very common and frequently unrecognized cause
• Pain — desire reasonably declines when sex hurts; this is a treatable cause masquerading as a desire problem
• Sleep and fatigue
• Relationship and psychological factors, which are frequently the dominant input
• Depression and anxiety, and their treatments

Treating a desire complaint pharmacologically while dyspareunia, an SSRI, or an unaddressed relationship issue drives it will disappoint. Our overview of peptide and hormone therapy for menopause covers the hormonal contributors.

Testosterone in Women

Testosterone therapy for low desire in postmenopausal women has a real evidence base and is used off-label, since no female-specific product is FDA-approved in the US. Compounded preparations allow appropriate female dosing, which is a fraction of male dosing — this is a place where using a male product at a reduced amount is not adequate.

Compounded PT-141

Compounded bremelanotide preparations exist and are used off-label, including in postmenopausal women where the approved product's indication does not extend. Off-label prescribing is legal and common, but patients should understand they are outside the population in which efficacy was established. Compounding status should be verified on the FDA peptide status tracker.

Related reading: Newtropin's women's hormone & peptide therapy program

Frequently Asked Questions

Does PT-141 work for women?

Bremelanotide is FDA-approved for hypoactive sexual desire disorder in premenopausal women, based on trials showing statistically significant improvements in desire and associated distress. Effect sizes were modest.

How is PT-141 different from Viagra?

PT-141 acts centrally on melanocortin receptors affecting sexual desire. PDE5 inhibitors such as sildenafil act on blood flow. Desire and vascular response are different mechanisms, which is why vascular agents have performed poorly in women.

Is PT-141 approved for postmenopausal women?

No. The approval covers premenopausal women; efficacy was not established in postmenopausal women. Compounded use in that population is off-label.

What are the side effects?

Nausea is most common, affecting roughly 40% in trials and causing meaningful discontinuation. Flushing, headache, transient blood pressure increase, and focal hyperpigmentation with frequent use are also reported.

How often can PT-141 be used?

The approved product is limited to one dose in 24 hours and no more than eight per month, largely because of the hyperpigmentation risk with frequent use.

What else causes low libido in women?

Hormonal changes, SSRIs and other medications, pain with intercourse, sleep deprivation, depression and anxiety, and relationship factors. Most presentations have more than one contributor, which is why evaluation matters before treatment.